|
|
|
|
LEADER |
01882nam a2200289 u 4500 |
001 |
EB002002371 |
003 |
EBX01000000000000001165272 |
005 |
00000000000000.0 |
007 |
tu||||||||||||||||||||| |
008 |
210907 r ||| eng |
245 |
0 |
0 |
|a Genetic susceptibility to breast and ovarian cancer
|h Elektronische Ressource
|b assessment, counseling, and testing guidelines
|
260 |
|
|
|a Bethesda (MD)
|b American College of Medical Genetics
|c 1999, 1999
|
300 |
|
|
|a 1 online resource
|
505 |
0 |
|
|a Includes bibliographical references
|
653 |
|
|
|a Genetic Predisposition to Disease
|
653 |
|
|
|a Primary Health Care / methods
|
653 |
|
|
|a Genetic Testing
|
653 |
|
|
|a Ovarian Neoplasms / genetics
|
653 |
|
|
|a Breast Neoplasms / genetics
|
653 |
|
|
|a Genetic Counseling
|
710 |
2 |
|
|a American College of Medical Genetics
|
041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
500 |
|
|
|a Title form HTML header
|
856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK56955
|3 Volltext
|n NLM Bookshelf Books
|3 Volltext
|
082 |
0 |
|
|a 610
|
520 |
|
|
|a The Guidelines have been prepared to help the primary care provider to participate in the pre- and post-test education and counseling required for every patient contemplating genetic testing for breast and ovarian cancer. Although some important genetic, epidemiological, and clinical issues remain unresolved, it is essential that all health care providers understand the familial basis of some cancers and the potential applications of genetic testing as part of the risk assessment process. The Guidelines do not comment on who should provide the counseling, nor try to demarcate where risk assessment leaves off and genetic counseling begins. It is hoped that the enhanced collaborative relationships encouraged in the Guidelines will improve quality of care provided to all patients
|